Live Breaking News & Updates on Nasdaq Rlay|Page 12
Stay updated with breaking news from Nasdaq rlay. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Relay Therapeutics (NASDAQ:RLAY – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday, Zacks.com reports. The brokerage currently has a $31.00 price target on the stock. Zacks Investment Research‘s price objective would suggest a potential upside of […] ....
Relay Therapeutics (NASDAQ:RLAY – Get Rating) and CEL-SCI (NYSE:CVM – Get Rating) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, risk, earnings, valuation and institutional ownership. Risk and Volatility Relay Therapeutics has a beta of 1.66, meaning […] ....
Analysts expect that Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Rating) will post ($0.63) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have provided estimates for Relay Therapeutics’ earnings. The lowest EPS estimate is ($0.64) and the highest is ($0.63). Relay Therapeutics posted earnings of ($0.47) per share in the same quarter […] ....
Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Rating)’s share price gapped down prior to trading on Wednesday after an insider sold shares in the company. The stock had previously closed at $34.88, but opened at $31.40. Relay Therapeutics shares last traded at $31.29, with a volume of 12,657 shares changing hands. Specifically, insider Donald A. Bergstrom […] ....
Brown Advisory Inc. acquired a new position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Rating) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 12,914 shares of the company’s stock, valued at approximately $397,000. Other institutional investors and hedge […] ....